Team

Shanmugavel Madasamy, Ph.D., MLS(ASCP)Founder, CEO

Dr. Madasamy has extensive research experience in the area of Vascular Biology gained from both academic and start-up biotech environments. After receiving a Ph.D. in Biotechnology from Anna University, India, in 1997, he pursued his postdoctoral research at Iowa State University, Iowa. He worked as a Senior Scientist until 2004 at the Division of Vascular Biology, Torrey Pines Institute for Molecular Studies (TPIMS) in San Diego. His research focused on bioengineering human fibrinolytic (blood clot dissolution) enzymes. Prior to founding Plaxgen, he worked as a Staff Scientist at Catalyst Biosciences in South San Francisco from 2004 to mid-2007. At Catalyst Biosciences, he was involved in the development of the company’s protease screening technology platform. At Plaxgen, Dr. Madasamy led the development of the Plaque Array technology and the serum-based plaque-load and statin-response tests for the diagnosis of cardiovascular and Alzheimer’s diseases. He has authored many peer-reviewed research articles and has both issued and pending patents.


Alan Wu, Ph.D., D.ABCC Director, Clinical Laboratory

Dr. Wu is internationally known in the fields of clinical chemistry, toxicology, cardiac biomarkers and pharmacogenomics. He earned his B.S. degree in Chemistry and Biology at Purdue University and received a Ph.D. in Analytical Chemistry from the University of Illinois. He was trained in clinical chemistry at Hartford Hospital and, thereafter, became a diplomate of the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. In 1982, he accepted a position as Assistant Professor of Pathology at the University of Texas Medical School, Houston, and was Associate Director of Clinical Chemistry at Hermann Hospital. He returned to Hartford Hospital in 1992 to become Director of the Chemistry and Toxicology Laboratories and became Professor of Laboratory Medicine and Adjunct Professor of Chemistry at the University of Connecticut Farmington and Storrs CT campuses, respectively. In 2004, he became the Director of Chemistry and Toxicology at San Francisco General Hospital and Professor of Laboratory Medicine at the University of California, San Francisco (UCSF). Dr. Wu has over 500 peer-reviewed and non-peer-reviewed publications, book chapters and books, as well as hundreds of published abstracts. Since 1999, he has been Editor-in-Chief of Clinica Chimica Acta. He has received numerous awards from the American Association for Clinical Chemistry.


Ahmad Salehi, M.D., Ph.D.Director, Neurosciences Initiatives

Dr.Salehi is a clinical professor affiliated with Stanford Medical School, Stanford University and has more than 20 years of experience in the field of Alzheimer’s disease and Down syndrome. Prior to this position, he was a Senior Research Scientist at the Department of Neurology and Neurological Disorders, Stanford School of Medicine. In 2010, he received the World Technology Award in the field of Biotechnology from the World Technology Network in Manhattan. His publications in top-tier journals have been featured around the world and many have been featured on the cover. During his postdoctoral training at the Netherlands Institute for Brain Research, he was chosen as the best junior scientist in the field of Alzheimer’s disease in the country.



Ravikumar Ponnusamy, Ph.D.Director, Neuroscience Technology Development

Dr. Ponnusamy is a neuroscientist with 20 years of research experience. He received his PhD from the Department of Psychopharmacology at National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India. After receiving PhD, he joined Brain Research Institute, University of California, Los Angeles, to pursue his postdoctoral research on fear and anxiety disorders including Post Traumatic Stress Disorders (PTSD). Later he directed neurobehavioral core research laboratories at UCLA and Gladstone Institutes, University of California, San Francisco and collaborated with a wide variety of laboratories to prevent, reduce or reverse cognitive dysfunctions in neurological and psychiatric diseases. Recently he was a health scientist at VA Palo Alto, Stanford University School of Medicine in the field of Down Syndrome. He has published numerous high-profile papers in the fields of PTSD, Traumatic Brain Injury, and Alzheimer’s disease. He is also an advisor to SPARK translational program at Stanford University.


Edward P. Amento, M.D. Scientific Advisor

Dr. Amento is Founder and Executive Director of the Molecular Medicine Research Institute (MMRI) in Sunnyvale, CA. He is a founder of Connetics Corporation (formerly Connective Therapeutics, Inc.), where he held executive positions, and of Theracos, Inc., where he served as founding CEO and President. Earlier, he held senior positions at Genentech. He is also an Adjunct Clinical Professor of Medicine at Stanford University School of Medicine. Prior to his Stanford appointment, Dr. Amento was a faculty member at Harvard Medical School and the Massachusetts General Hospital. He is the author or co-author of more than 160 published manuscripts, reviews, chapters and abstracts. He also serves on the Board of Directors and Scientific Advisory Board of several privately held biotechnology companies. Dr. Amento’s research and clinical interests are directed toward the understanding and treatment of chronic diseases associated with inflammation and altered extracellular proteins.



Elliott Mufson, Ph.D. Scientific Advisor

Dr. Mufson is an Alzheimer’s Disease researcher at Barrow Neurological Institute as an Institutional Professor in the Division of Neurobiology. Dr. Mufson is the director of several active grants, including a National Institute on Aging-supported Program Project grant entitled the “Neurobiology of Mild Cognitive Impairment (MCI) in the Elderly” and a Department of Defense grant to study brain trauma. Dr. Mufson received his doctorate in biological psychology from Downstate Medical Center, New York, and was a postdoctoral fellow and an assistant professor in neuroscience in the Department of Neurology at Beth Israel Hospital, Harvard Medical School. While there, he produced a series of classic papers on the connectivity and chemistry of the central cholinergic system in the forebrain and brainstem, a crucial brain region involved in the onset of Alzheimer’s disease (AD).During the late 1980s, Dr. Mufson became the Associate Director of the Sun Heath Research Institute, Sun City, Arizona, where he assisted in the development of a brain bank. In 1991, Dr. Mufson was recruited to the Department of Neurological Sciences at Rush University Medical Center, in Chicago, to develop a research program in the molecular biology of pre-symptomatic AD. Dr. Mufson is a pioneer in the application of single cell gene array technology to study the genetic signature of neurons during the progression of AD. He has published 297 peer-reviewed articles and more than 40 book chapters. In 2010, the Information Sciences Institute recognized Dr. Mufson as one of the 100 most highly cited researchers in neuroscience.


J. Paul Robinson, Ph. D Scientific Advisor

Dr. Robinson is an internationally recognized scientific expert in the area of Flow cytometry. Dr. Robinson is the SVM Professor of Cytomics in the College of Veterinary Medicine, a professor of biomedical engineering in the Weldon School of Biomedical Engineering, as well as the director of the Purdue University Cytometry Laboratories at Purdue University. He is the Editor-in-Chief of Current Protocols in Cytometry, and Associate Editor of Histochemica et Cytobiologica. He received his Ph.D. in Immunopathology from the University of New South Wales, Sydney, Australia and completed a postdoctoral fellowship at the University of Michigan Medical School. In 2004, he was elected to the College of Fellows, American Institute for Medical & Biological Engineering (AIMBE) and received the Pfizer Award for Innovative Research. Dr. Robinson’s research area has been focused on reactive oxygen species primarily in neutrophils and cell lines such as HL-60 cells.


Yuri L. Lyubchenko, Ph.D., DSc Scientific Advisor

Dr. Lyubchenko is a professor at Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE. He received his doctoral training and Doctor of Science degree from Molecular Biophysics at the Moscow Institute of Physics and Technology. His current research at the University of Nebraska focuses on understanding fundamental mechanisms underlying health and disease, which are key to developing new and more effective diagnostics and medications. The research is categorized into three broad areas, with interplay and overlap among them (1) Structural genomics in relation to cancer and other diseases, (2) Molecular mechanisms Alzheimer’s, Parkinson’s and other protein aggregation diseases, (3) Protein-DNA interactions for novel approaches for HIV restriction. He is the author or co-author of more than 140 published research articles, reviews, and abstracts. His research projects are supported by NSF and NIH grants.


Marty Bigos Scientific Advisor

A visionary and expert in the flow cytometry field, Mr. Bigos has more than 25 years of experience in cell and particle analysis research employing advanced flow cytometry platforms. He is currently Director of the Shared FACS Facility at Stanford University. Prior to this position, he was a research scientist and Flow Cytometry Core Director at the J. David Gladstone Institutes, University of California, San Francisco (UCSF). Since 1984, he has held research specialist and Operations Manager positions in cell analysis research programs in both Stanford University and UCSF. He has been involved in organizing many flow cytometry conferences and also trained numerous graduate students and researchers in Stanford University and UCSF. Mr.Bigos has a significant publications record in peer-reviewed journals in the field of cytometry and many issued patents related to flow cytometry applications. He has been a member of NIH/NCRR and SBIR/STTR study review committees.